However, such testing and prescriptions still trail behind the CDC recommendations.
Transgender persons have increased risk for HIV infection, with estimated prevalence of 14.1% for transgender women (TGW) and 3.2% for transgender men (TGM), with higher rates among Black and Latino individuals. Medical appointments for gender-affirming hormone therapy represent opportunities for HIV testing and PrEP prescribing. Using a U.S. commercial insurance database, investigators identified adults with transgender-related diagnostic codes between 2014 and 2021.
Transgender-related diagnoses increased from 13.4 to 113.9 per 100,000 insured persons, primarily driven by those aged 18–34 years. Prescription of gender-affirming hormone therapy also increased (from 30.5% to 43.4% of transgender individuals). Approximately 2.4% of TGW and 0.…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)